Episode Details

UVM Health is cutting coverage for weight loss drugs like Ozempic and Zepbound starting September, aiming to save $19 million annually to shield employees from rising premiums — but the move sparks outrage as monthly out-of-pocket costs could hit $800–$1,200, forcing some to consider quitting their jobs. While these drugs, originally for diabetes, show promise for weight, sleep apnea, and heart health, the hospital cites studies showing limited long-term cost savings and high dropout rates. Meanwhile, Medicare quietly launches a pilot to test if these drugs can reduce overall healthcare spending — a gamble that could reshape how insurers handle obesity treatment.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/1834d3c178764045